California - The U.S. Patent and Trademark Office granted a patent for Amarin Corporation's AMR101 last week. The field of pharmaceutical patents is hugely competitive and companies are constantly under pressure to develop new and more effective prescriptions. As such, AMR101 is a key product in the pharmaceutical company's portfolio. As a treatment for high triglycerides, AMR101 is currently undergoing FDA approval, with a decision due in July. In the meantime, Amarin has announced that its product has been successful in multiple Phase III trials. With such positive feedback and test results, AMR101 is primed for success in the marketplace. As a result, the outlook for FDA approval of AMR101 is also extremely positive.
Among the existing pharmaceutical companies, Amarin is in a particularly attractive position because of its current cash value and its prospects for production of many popular patents that have recently expired. Companies seeking to increase their market share of prescriptions can easily pick up production on these expired patents. In addition, there are a number of larger companies such as Pfizer, GlaxoSmith and Human Genome Sciences looking for partnerships. Amarin could easily partner with one of the larger companies and dramatically increase its market share in the field of biopharmaceuticals. Consequently, Amarin could be in prime market position to top the list of hot prospects in 2013 and beyond.
Amarin is a biopharmaceutical company focused primarily on improving treatment of cardiovascular disease. With its U.S. headquarters in Bedminster, New Jersey, Amarin has demonstrated a history of expertise in lipid science and the use of essential fatty acids in treating cardiovascular disease. The therapeutic benefits of AMR101 are intended for patents with high trigylcerides, who are also on statin therapy for elevated LDL-cholesterol levels. It is estimated that over 40 million people suffer from dangerously elevated levels of triglycerides. As a result of these elevated levels, patients have an increased risk of developing coronary artery disease, diabetes and obesity, among other problems. AMR101 is being positioned as a best-in-class prescription for treating these patients and offering them better health, free from diseases caused by elevated triglycerides.